Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836069 · ClinicalTrials.gov registry record · Phase 3
Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
A Phase 3 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT00836069 is a Phase 3 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT00836069, a Phase 3 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, parallel-group, multi-site, Phase 3, placebo controlled fixed-dose study of PD 0332334 and paroxetine in 528 outpatients with generalized anxiety disorder. Subjects will be randomized to the following treatments (132 subjects per treatment group): PD 0332334 225 mg twice a day (450 mg/day), PD 0332334 300 mg twice a day (600 mg/day), placebo once a day in the morning or paroxetine 20 mg once a day in the morning (20 mg/day).
Interventions
- DRUG Placebo
- DRUG Paroxetine
- DRUG No drug name provided by Sponsor; drug referenced as PD 0332334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00836069
The ClinicalTrials.gov registry entry for NCT00836069 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00836069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00836069 about?
NCT00836069 is a clinical study titled "Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder". This study is a randomized, double-blind, parallel-group, multi-site, Phase 3, placebo controlled fixed-dose study of PD 0332334 and paroxetine in 528 outpatients with generalized anxiety disorder. Subjects will be randomized to the following treatments (132 subjects per treatment group): PD 033233...
What is the current status of trial NCT00836069?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2008-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00836069?
The interventions under investigation include: Placebo (DRUG), Paroxetine (DRUG), No drug name provided by Sponsor; drug referenced as PD 0332334 (DRUG).
Who is sponsoring clinical trial NCT00836069?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.